XML 87 R35.htm IDEA: XBRL DOCUMENT
v3.26.1

Contract revenues and other operating income - Anti-Abeta Active Immunotherapy in AD - 2026 amendment agreement Takeda Pharmaceuticals, USA, Inc. (Details) SFr in Thousands, $ in Millions | 1 Months Ended | 6 Months Ended |  |
--- | --- | --- | --- | ---
Apr. 30, 2026 CHF (SFr) | Apr. 30, 2026 USD ($) | Jun. 30, 2026 CHF (SFr) | Jun. 30, 2025 CHF (SFr) | Jun. 30, 2026 USD ($) | Dec. 31, 2025 CHF (SFr)
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |  |
Contract revenue |  |  | SFr 16,232 | SFr 2,296 |  |
Short-term deferred contract revenue |  |  | 89,477 |  |  | SFr 83,706
Current trade receivables |  |  | 9,922 |  |  |
Anti-Abeta Active Immunotherapy in AD - 2026 amendment agreement Takeda Pharmaceuticals, USA, Inc. |  |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |  |
Value of milestone reached during the period | SFr 9,500 | $ 12.0 |  |  |  |
Contract revenue |  |  | 3,100 |  |  |
Short-term deferred contract revenue |  |  | 6,400 |  |  |
Current trade receivables |  |  | SFr 9,800 |  | $ 12.0 |

X
- Definition Value of milestone reached during the period. + References No definition available. + Details
Name: | aciu_ValueOfMilestoneReachedDuringPeriod
Namespace Prefix: | aciu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of current contract liabilities. [Refer: Contract liabilities] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2025-01-01 -Paragraph 105 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_105&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_CurrentContractLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of current trade receivables. [Refer: Trade receivables] + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph B9 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B -URIDate 2025-03-27 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Note Expiry date 2027-01-01 -Name IAS -Number 1 -IssueDate 2025-01-01 -Paragraph 68 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_68&doctype=Standard -URIDate 2025-03-27 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Note Expiry date 2027-01-01 -Name IAS -Number 1 -IssueDate 2025-01-01 -Paragraph 78 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_CurrentTradeReceivables
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2025-01-01 -Paragraph 114 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_114&doctype=Standard -URIDate 2025-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2025-01-01 -Paragraph 113 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_113_a&doctype=Standard -URIDate 2025-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 103 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard -URIDate 2025-03-27 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 103 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_TypesOfContractsAxis=aciu_AntiAbetaActiveImmunotherapyInAd2026AmendmentAgreementTakedaPharmaceuticalsUsaInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |